Want to see JP:4978 full AI Analyst Report?
4978 Stock Chart & Stats
¥143.00
¥3.00(2.91%)
At close: 4:00 PM EST
¥143.00
¥3.00(2.91%)
Day’s Range― - ―
52-Week Range¥117.00 - ¥242.00
Previous CloseN/A
Volume331.50K
Average Volume (3M)602.67K
Market Cap
¥14.74B
Enterprise Value¥6.25K
Total Cash (Recent Filing)¥5.62B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.59
Shares Outstanding101,011,894
10 Day Avg. Volume408,470
30 Day Avg. Volume602,666
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.88
Price to Sales (P/S)7.46
P/FCF Ratio-34.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.7
Revenue Forecast (FY)¥3.53B
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetEffectively no debt and a substantial, stable equity base provide a meaningful capital buffer. This reduces financial risk, limits interest burden, and gives ReproCELL more flexibility to sustain research investments or manage operating volatility over the next several quarters.
Research-focused Revenue ModelThe combination of product sales and fee-based research services gives ReproCELL multiple ways to monetize its stem-cell and iPSC capabilities. Serving pharmaceutical, biotech, and academic research workflows can support recurring customer relevance as cell-based research expands.
Solid Gross Profit BaseMaintaining more than ¥1.0B of gross profit indicates that the company retains meaningful economic value in its offerings even during a weaker revenue period. This provides a foundation for future operating improvement if sales stabilize and costs become better aligned.
Bears Say
Revenue VolatilityThe shift from strong growth to repeated declines shows that demand and execution have not yet produced a predictable expansion path. Continued revenue volatility can make staffing, research investment, and operating-cost planning difficult, weakening confidence in near-term earnings durability.
Persistent Cash BurnPersistent negative free cash flow indicates that operations have not been self-funding, even when reported net income was positive. Ongoing cash consumption can constrain investment choices and increase reliance on the company’s capital buffer to support research and commercial activities.
Weak ProfitabilityThe return to substantial losses after only a brief profitable period highlights weak earnings consistency and limited operating leverage. Gross profit has not been sufficient to cover costs reliably, leaving the business sensitive to revenue fluctuations and execution setbacks.
4978 FAQ
What was ReproCELL Inc.’s price range in the past 12 months?
ReproCELL Inc. lowest stock price was ¥117.00 and its highest was ¥242.00 in the past 12 months.
What is ReproCELL Inc.’s market cap?
ReproCELL Inc.’s market cap is ¥14.74B.
When is ReproCELL Inc.’s upcoming earnings report date?
ReproCELL Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 60 days.
How were ReproCELL Inc.’s earnings last quarter?
ReproCELL Inc. released its earnings results on Aug 13, 2026. The company reported -¥1.56 earnings per share for the quarter.
Is ReproCELL Inc. overvalued?
According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued.
Does ReproCELL Inc. pay dividends?
ReproCELL Inc. does not currently pay dividends.
What is ReproCELL Inc.’s EPS estimate?
ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ReproCELL Inc. have?
ReproCELL Inc. has 101,011,894 shares outstanding.
What happened to ReproCELL Inc.’s price movement after its last earnings report?
ReproCELL Inc. reported an EPS of -¥1.56 in its last earnings report. Following the earnings report the stock price went up 0.714%.
Which hedge fund is a major shareholder of ReproCELL Inc.?
Currently, no hedge funds are holding shares in JP:4978
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ReproCELL Inc.
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.